Open Payments

PATRICK R. YASSINI

Type
Physician · Allopathic & Osteopathic Physicians / Family Medicine
Where
Coronado, CA
NPI
1649353095
Received
$169,379 in 10 records, 2021 to 2025 ($281 general, $169,098 research)
As principal investigator
$2,567,645 of research payments to others in 653 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment1$23
2022General payment4$198
2022Research payment2$169,098
2021General payment3$60

By company

CompanyRecordsAmountYears
Valneva Austria GmbH2$169,0982022
Lumenis BE inc1$1412022
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.2$312022
Linus Health, Inc.1$252022
MERZ NORTH AMERICA, INC.1$232024
Novo Nordisk Inc1$222021
Clarus Therapeutics Inc.1$202021
Biohaven Pharmaceuticals, Inc.1$162021

By nature of payment

NatureRecordsAmount
Research payment2$169,098
Food and Beverage8$281

Records

DateCompanyAmountNatureFormProductStudyYear
2024-10-07MERZ NORTH AMERICA, INC.$23Food and BeverageIn-kind items and servicesXeomin Biological, Dermatology2024
2022-08-17BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$17Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PRIMARY CARE2022
2022-05-17Lumenis BE inc$141Food and Beverage (4 payments)Cash or cash equivalentOptiLight Device, Opthamology2022
2022-03-28Valneva Austria GmbH$87,208Research paymentCash or cash equivalentA MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A L2022
2022-03-14Valneva Austria GmbH$81,889Research paymentCash or cash equivalentA MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A L2022
2022-03-11BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.$13Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PRIMARY CARE2022
2022-02-08Linus Health, Inc.$25Food and BeverageIn-kind items and servicesCORE COGNITIVE EVALUATION Device, DEVICE2022
2021-12-22Clarus Therapeutics Inc.$20Food and BeverageIn-kind items and servicesJATENZO Drug, Testosterone Replacement Therapy2021
2021-12-07Novo Nordisk Inc$22Food and BeverageIn-kind items and servicesRYBELSUS Drug, Diabetes2021
2021-12-02Biohaven Pharmaceuticals, Inc.$16Food and BeverageIn-kind items and servicesNURTEC ODT Drug, PRIMARY CARE2021

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$2,780A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$911A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$637A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$330A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$330A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$330A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$330A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$330A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$330A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$330A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$330A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$330A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$330A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025
2025-12-18Seqirus USA IncApex Clinical Research$905A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of 2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Diego CountyCoronado city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Coronado, CA, county San Diego County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Coronado, CA
County
San Diego County, CA
State
California
Population B0100319,0153,288,77439,287,377
Population, 2020 census P120,1923,298,63439,538,223
Median age B0100242.037.337.9
Under 18 B0100117.8%20.9%22.0%
65 and over B0100122.1%15.4%15.7%
Households B110017,3031,171,27813,548,091
Foreign born B0500210.1%22.8%27.0%
Median household income B19013$134,534$106,268$99,122
Median family income B19113$166,058$122,377$113,346
Per capita income B19301$81,464$51,976$49,513
Poverty rate B170014.7%10.3%12.0%
Unemployment rate B230254.7%6.1%6.6%
Civilian labor force B230256,8051,689,38420,068,466
Mean commute (minutes) B0801318.125.528.7
Bachelor's degree or higher B1500365.5%43.2%37.1%
Housing units B250019,8961,250,64114,644,735
Owner-occupied B2500354.6%54.6%55.9%
Renters B2500345.4%45.4%44.1%
Median home value B25077$2,000,001$854,700$734,700
Median gross rent B25064$3,257$2,246$2,036
White, not Hispanic B0300267.8%42.4%33.8%
Black B030022.4%4.4%5.2%
Hispanic or Latino B0300220.2%34.6%40.2%
Asian B030023.3%12.1%15.3%
American Indian and Alaska Native B030020.4%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Coronado, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.